Australia Stock Exchange release from PHARMAUST : Preliminary MPL antiviral leukaemia preclinical WEHI results
23/02/2022 24:00
Australia Stock Exchange release from PHARMAUST PAA.AX : Preliminary MPL antiviral leukaemia preclinical WEHI results
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO